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Abstract 
Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug 
delivery. In the current study, we have investigated ACT in combination with paclitaxel and 
Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In 
combination with paclitaxel (12 mg/kg given i.p)., ACT induced a strong increase in therapeutic 
efficacy; 120 days after study start, 42% of the animals were in stable, complete remission vs. 
0% for the paclitaxel only group and the median survival was increased by 86%. In combination 
with Abraxane® (12 mg paclitaxel/kg given i.v.), ACT induced a strong increase in the 
therapeutic efficacy;  60 days after study start 100% of the animals were in stable, remission vs. 
0% for the Abraxane® only group, 120 days after study start 67% of the animals were in stable, 
complete remission vs. 0% for the Abraxane® only group. For the ACT + Abraxane group 100% 
of the animals were alive after 120 days vs. 0% for the Abraxane® only group. Proof of concept 
for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic 
efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in 
mice. 
 
Keywords: Acoustic Cluster Therapy, ACT, targeted drug delivery, Abraxane®, paclitaxel, PC-3 
prostate adenocarcinoma, pre-clinical. 
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1. Introduction 
Inadequate delivery into solid tumors is a well-recognized problem for a wide variety of 
chemotherapeutic agents, including small molecules, macromolecules such as monoclonal 
antibodies and cytokines, and larger constructs such as liposomes or other nanoparticles. Once 
administrated into the circulation, endothelial cells and other biological barriers restrict their 
passive extravasation into the tissue of the targeted pathology. Delivery of a systemically 
administrated agent to cells within solid tumors involves three processes: distribution through 
the vascular compartment, transport across the microvascular wall, and dispersion within the 
tumor interstitium [1, 2]. However, for a number of drugs, the current, passive transvascular 
delivery paradigm, even when taking advantage of the Enhanced Permeability and Retention 
(EPR) effect or biochemical mechanisms, is inefficient and, together with poor penetration 
through the tumor interstitium, the drug often does not reach effective local concentrations 
with an inadequate therapeutic effect being the outcome. In combination with low therapeutic 
indexes, increasing the systemic dosages is not a viable strategy due to serious and wide spread 
adverse effects, overall limiting the clinical utility of a range of potent drugs. 
For decades, scientists and the pharmaceutical industry have tried to find ways to enhance the 
efficacy of therapeutic agents with various approaches designed for specific delivery or 
enhanced uptake of the drug within the targeted pathology (i.e. targeted drug delivery). 
Successful strategies of this type may offer ways to increase the bioavailability and/or minimize 
systemic exposure, improving the therapeutic efficacy and reducing serious side effects [1-4]. 
Numerous drug carrier concepts, e.g. liposomes, micelles, dendrimers and nanoparticles have 
been employed, either to passively make use of the EPR effect, or in combination with surface 
ligands that actively promote accumulation in tumor tissue through biochemically affinity to 
specifically expressed target groups. In addition, active transport using human serum albumin 
has been exploited to target tumor tissue [5, 6]; e.g. Abraxane® (nab-paclitaxel, paclitaxel 
bound to albumin). 
However, even though huge resources have been spent on finding functional concepts for 
targeted drug delivery over the last two decades, and despite promising pre-clinical results for 
several of these, there has been very limited transition to drug products and clinical practice. In 
truth, the objective remains essentially unresolved in current standard of care medicinal 
therapy. 
In recent years, several concepts for ultrasound (US) mediated, targeted drug delivery have 
been investigated, some with quite encouraging results [7-12]. Many of the these approaches 
explore the use of regular US contrast microbubbles such as Sonovue™ (Bracco Imaging S.p.A, 
Italy) or Optison™ (GE Healthcare AS, Norway) co-injected with various drug formulations. 
Insonation of the target pathology, containing microbubbles and drug in vascular 
compartments, leads to a variety of biomechanical effects that increase the permeability of the 
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endothelial barrier leading to enhanced extravasation, distribution and uptake of drug 
molecules to target tissue [13-15]. Co-injection of Gemcitabine and Sonovue, with localized US 
insonation for enhanced drug uptake and therapeutic effect during treatment of pancreatic 
ductal adenocarcinoma is currently being explored in clinical trials [16]. A similar approach is 
being investigated for treatment of glioblastoma in humans [17, 18]. Whereas various drug 
delivery approaches exploring the use of microbubbles have shown some promise, several 
issues hamper their effectiveness. Being small, the magnitude of the biomechanical work they 
can induce is relatively limited. In addition, being free flowing they display limited contact with 
the endothelial wall, reducing the level and range of the biomechanical effects [14]. 
Furthermore, microbubbles are typically cleared from vascular compartments within 2-3 
minutes and, finally, to produce sufficient biomechanical work and effect levels, microbubbles 
often need a high US intensity that induces inertial cavitation, with ensuing safety issues. 
Recently, a novel approach for US mediated, targeted drug delivery; Acoustic Cluster Therapy 
(ACT), has been suggested [19]. ACT exploits mechanisms that are related to those employed by 
regular microbubbles, but addresses important shortcomings of the latter. Details and 
attributes of the ACT formulation concept are described in [20, 21]. In brief, the approach 
comprises co-administration of a drug together with a dispersion of microbubble/microdroplet 
clusters, followed by a two-step, local US activation and delivery enhancement procedure. US 
activation induces a liquid-to-gas phase shift of the microdroplet component and the formation 
of large (~ 25 µm) bubbles that transiently lodge in the targeted microvasculature, occluding 
blood flow. The subsequent US enhancement step induces controlled volume oscillations that 
lead to enhanced local permeability of the vasculature, allowing for improved extravasation and 
distribution of drug into the tumor tissue extracellular matrix. The ACT concept represents an 
unprecedented approach to targeted drug delivery that may improve significantly the efficacy 
of e.g. current chemotherapy regimen. 
In our previous papers [20-22] we have described the basics of the ACT formulation and 
concept, shown the attributes of the large, activated bubbles in-vivo, and provided proof of 
principle for targeted, tumor specific uptake. In the current paper, we demonstrate proof of 
concept for this new treatment strategy by evaluating synergistic effects from combining ACT 
with paclitaxel and nab-paclitaxel (Abraxane®) for treatment of human prostate 
adenocarcinoma in mice. 
 
2. Materials and Methods 
2.1 Mice and Tumors 
PC-3 human prostate adenocarcinoma cells (American Type Culture Collection, USA) were 
cultured in Dulbecco’s modified Eagle medium (Life Technologies, USA) with 10% fetal bovine 
serum at 37°C and 5% CO2. Female athymic nude mice Balb/c nude mice (HsdOla: MF1-
Foxn1nu, Envigo, Netherlands) were purchased at 6-8 week of age. The animals were housed in 
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groups of five in individually ventilated cages (IVCs) (Model 1284 L, Techniplast, France). Mice 
were housed under conditions free of specific pathogens according to the recommendations 
set by the Federation for Laboratory Animal Science Associations [23]. The mice also had free 
access to food and sterile water and a controlled environment with temperatures kept between 
19 and 22°C and relative humidity between 50% and 60%. All experimental animal procedures 
were in compliance with protocols approved by the Norwegian National Animal Research 
Authorities. Before tumor implantation, mice were anesthetized with isoflurane, and a 50 µl 
suspension containing 3x106 PC-3 cells was slowly injected subcutaneously on the lateral aspect 
of the left hind leg between the hip and the knee. Tumors were allowed to grow for ~ 4 weeks 
until the volume of the tumor was between 100 and 200 mm3. Anesthesia was induced by 
subcutaneous (s.c.) injection of midazolam (5 mg/kg)/fentanyl (0.05 mg/kg)/medetomidin (0.5 
mg/kg) prior to each intervention described below. One hour after treatment, an antidote for 
sedation and anesthesia (atipamezol (2.5 mg/kg) and flumazenil (0.5 mg/kg)) was injected s.c. 
to wake up the mouse. Mice were kept for a minimum of 5 hours in a recovery chamber after 
treatment. During all experiments the mouse body temperature was kept constant.  
 
2.2 Test Items 
Test items were kindly provided by Phoenix Solution AS, Oslo, Norway. In brief, the ACT 
compound investigated consisted of a dispersion of microbubble/microdroplet clusters made 
from reconstituting the ultrasound contrast agent Sonazoid™ (GE Healthcare AS, Oslo, Norway) 
with 2 ml of perfluoromethylcyclopentane (PFMCP) microdroplets (3 µl/ml) stabilized with a 
distearoyl-phosphatidylcholine (DSCP) phospholipid membrane with 3% (mol/mol) 
stearlyamine (SA), dispersed in 5 mM TRIS buffer. Further details on the ACT formulation are 
provided in [21]. 
Cytotoxic drugs investigated: Paclitaxel 6 mg/ml (Fresenius Kabi AB, Uppsala, Sweden) via i.p. 
injection and Abraxane™ 5 mg/ml (Celgene Ltd., Uxbridge, Great Britain) via i.v. injection.  
 
2.3 Experimental set up 
The experimental set up was as previously described [22]. In brief, total insonation duration 
was 5 minutes and 45 seconds. Initially, for activation (Activation US) of the clusters, the tumor 
was insonated for 45 seconds using a clinical broad-bandwidth phased array probe (Vscan, GE 
Healthcare AS, Oslo, Norway), with a Fc 2.5MHz , 64 elements, frame rate of 20 Hz, and nominal 
mechanical index (MI) of 0.8 (Peak Negative Pressure, PNP, of 1.2 MPa). Actual MI was 
measured by a calibrated hydrophone to be approx. 0.4 (PNP of approx. 0.6 MPa) in the 
insonated tumor volume. Secondly, for the enhancement step (Enhancement US), after 
activation, the tumor tissue was insonated for 5 minutes with 500 kHz US at an MI of 0.2 (PNP 
of 0.14 MPa) using a custom made transducer (Imasonic SAS, Voray-sur-l'Ognon, France). 
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2.4 Groups, treatment regimens and responses. 
The study comprised eight groups, 7-10 animals in each, as detailed in Table 1. When the 
tumour size reached 100-200 mm3 the mice were enrolled into the study. Treatment was given 
once a week for 4 weeks on days 0, 7, 14 and 21. Paclitaxel, given intraperitoneal (i.p.) 1 hour 
before i.v. injection of ACT at a dose of 12 mg/kg, and Abraxane®, injected intravenously (i.v.) at 
a paclitaxel dose of 12 mg/kg, was administered immediately prior i.v. injection of ACT (5 mg 
pFMCP/kg) or Sonazoid™ (8 µl PFB/kg). For activation, immediately after ACT injection, the 
tumor was insonated for 45s using the clinical VScan system. For enhancement, immediately 
after activation, the tumor tissue was insonated for 5 minutes, using the Imasonic, 500 kHz 
transducer. ACT and Sonazoid™ treatment were repeated three consecutive times at each 
cycle. 
Animals were monitored for body weight and tumor size measured by caliper twice weekly for 
120 days after study start. Animals were sacrificed when they reached the institutional ethical 
endpoint associated with tumor burden (tumor size >15mm or weight loss >15%. A subset of 5 
animals were found dead one after day treatment, in which case they were included in the 
tumor growth data until that time point. Compared to similar studies [24], the number of 
unexplained fall outs are low in number, and these deaths are not considered to be treatment 
related. In the ACT+ABR group one animal, although its tumor was very small, was sacrificed in 
week 5 because of a necrotic tail at the ABR injection site. This animal was therefore excluded 
from the survival data. 
Only animals successfully undergoing procedures for the full 4 weeks were considered in the 
survival curves. The numbers of animal per group available for growth measurements were: 
control (9-9), Paclitaxel (9-9), Abraxane (10-9), ACT (9-8), ACT + PTX (10-7), ACT + ABR (10-10), 
Sonazoid + PTX (10-10), Sonazoid + ABR (9-9), where the range in numbers for a given group is 
the number of animals entering at week 0 and those completed the full 4 treatments. 
 
Table 1 – Study Design and treatment group 
Group Test item US procedure 
Control Saline None (sham treatment) 
Paclitaxel 12 mg Ptx/kg i.p. 45s 2.25 MHz/MI 0.4 + 5min 
0.5 MHz/MI 0.2 
Abraxane 12 mg Ptx/kg i.v. 45s 2.25 MHz/MI 0.4 + 5min 
0.5 MHz/MI 0.2 
ACT 3 x 5 mg pFMCP/kg i.v. 45s 2.25 MHz/MI 0.4 + 5min 
0.5 MHz/MI 0.2 
ACT + Paclitaxel 12 mg Ptx/kg i.p. + 3 x 5 mg pFMCP/kg i.v. 45s 2.25 MHz/MI 0.4 + 5min 
0.5 MHz/MI 0.2 
ACT + Abraxane 12 mg Ptx/kg i.v. + 3 x 5 mg pFMCP/kg i.v. 45s 2.25 MHz/MI 0.4 + 5min 
0.5 MHz/MI 0.2 
Sonazoid™ + Paclitaxel 12 mg Ptx/kg i.p. + 3 x 8 μl PFB/kg i.v 5min 45s 2.25 MHz/MI 0.4 
Sonazoid™ + Abraxane 12 mg Ptx/kg i.v. + 3 x 8 μl PFB/kg i.v 5min 45s 2.25 MHz/MI 0.4 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
6 
 
For ethical reasons, in compliance with the Norwegian National Animal Research Authorities 
rule to reduce the number of research animals as much as possible, drug + US-only nor 
Sonazoid™ + US only groups were not included in the study as the US exposure levels are well 
below such that might cause bioeffects, even in the presence of microbubbles [25, 26]. 
Similarly, Sonazoid nor ACT are, in the absence of US, not expected to affect tumor growth, and 
such groups were not included. 
 
2.5 Statistical Analysis 
Results for average tumor volume are expressed as mean ± standard error. Statistical 
comparisons of tumor size at various time points were performed using a two-tailed, two 
sample Student’s t-test assuming unequal variances. A p value less than 0.05 was considered 
statistically significant. 
 
 
3. Results 
3.1 Paclitaxel groups 
Results for average tumor size in paclitaxel and control groups are shown in Figure 1, results for 
tumor size of individual animals in the paclitaxel + ACT group are shown in Figure 2 and results 
for survival are shown in Figure 3. 
 
Figure 1. Average tumor size in groups as detailed in the legend, vs. time. PTX = 12 mg paclitaxel/kg 
i.p., ACT = 3 x 5 mg pFMCP/kg i.v., Sonazoid = 3 x 8 µl PFB/kg i.v. Four weekly treatment points are 
designated by vertical arrows. Error bars represent standard error of the mean. 
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Figure 2. Tumor size of individual animals in PTX + ACT group (cf. Figure 1 for details), vs. time. 
 
 
 
Figure 3 –Survival time curves paclitaxel treated animals. 
As can be observed from Figure 1, the paclitaxel and ACT monotherapies and the paclitaxel + 
Sonazoid™ groups did not display a significant effect on tumor growth rate vs. the saline control 
group. The paclitaxel + ACT group, however, shows a very strong inhibition of tumor growth 
rate, significantly different (p=0.0004) from all other groups three days after the first treatment.  
 
Four out of seven (58%) tumors started regrowing towards the end of or immediately after the 
end of the four-week treatment period. However, three tumors (42%) continued to regress to 
complete, stable remission after less than 60 days, which was kept for the duration of the study 
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(Fig 2). The median survival time was 52 days for the paclitaxel + ACT group vs. 28 days for the 
saline control group (Fig 3). 
 
3.2 Abraxane® groups 
Results for average tumor size in Abraxane® and control groups are shown in Figure 4, results 
for tumor size of individual animals in the Abraxane® and Abraxane® + ACT groups are shown in 
Figure 5 and results for survival are shown in Figure 6. 
 
Figure 4. Average tumor size in groups as detailed in the legend, vs. time. ABR = 12 mg paclitaxel/kg 
i.p., ACT = 3 x 5 mg pFMCP/kg i.v., Sonazoid = 3 x 8 µl PFB/kg i.v.  Four weekly treatment points are 
designated by vertical arrows. Error bars represent standard error of the mean. 
 
 
Figure 5. Tumor size of individual animals in Abraxane® (left) and Abraxane® + ACT (right) groups (cf. 
Figure 4 for details), vs. time. 
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Figure 6 –Survival time curves Abraxane ® treated animals. 
As can be observed from Figure 4, the Abraxane® monotherapy displayed a marked reduction 
in tumor growth rate vs. the saline control group, with significant differences (p=0.0009) from 
three days after the second treatment (day 10). The Abraxane® + ACT group, however, shows a 
very strong inhibition of tumor growth rate also vs. Abraxane® monotherapy, significantly 
different (p=0.002) three days after the first treatment.  
 
For the Abraxane® group, no tumors went to full remission and all tumors started regrowing 
between the end of the treatment regime and approx. 60 days. However, for the Abraxane® + 
ACT group, all tumors continued regression to complete remission after approx. 60 days and 6 
out of 9 tumors (67%) were in stable, complete remission at end of study. Only one of 9 tumors 
displayed significant regrowth 120 days after study start. The median survival time was 72 days 
for the Abraxane® group vs. 28 days for the saline control group. Median survival time for the 
Abraxane® + ACT group could not be determined, as all animals were alive at end of study. 
Based on the results displayed in Figure 6, however, it is estimated that the median survival 
time of this group would be at least 4 times that of the Abraxane® monotherapy group and 
possibly, indefinite. 
 
The ACT monotherapy group did not display significant effects on tumor growth rate vs. the 
saline control. Remarkably, this was the case for the Abraxane® + Sonazoid group as well.  
A summary of numeric responses for antitumor activity in all groups are given in Table 2. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
 
Table 2. Antitumor activity of paclitaxel / Abraxane® in combination with ACT. 
 
Treatment N TFS (%)1 Tumor doubling time (d), median (range)2 
Control 9 0 8.2 (6.1-11.4) 
PTX 9 0 8.6 (7.8-10.7) 
ABR 9 0 23.4 (15.3-37.5) 
ACT 8 0 9.4 (7.6-10.7) 
ACT + PTX 7 42 Partial-responders 17.0 (15.4-19.8) 
Responders infinite 
ACT + ABR 9 67 Infinite (64.9-infinite) 
Sonazoid + PTX 1
0 
0 7.9 (7.3-11.5) 
Sonazoid + ABR 9 0 8.2 (5.6-9.2) 
 
 
1 
Tumor free survivors after 120 days  
2
Tumor doubling times were calculated using the equation (t2-t1)ln2= ln(V2/V1). t1 = first treatment day, t2 is last 
measurement day, V1 is tumor volume on first treatment day, V2 is tumor volume at last measurement day. 
 
3.3 Tolerability 
No treatment related weight changes (Figure 7) were observed and no adverse events or signs 
of distress were observed during or immediately after treatment. 
 
 
Figure 7. Animal weights for all groups vs. time (average group weight at each monitoring point). 
4. Discussion 
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The two therapeutic regimes studied, although in principal investigating the same active 
ingredient, are quite different. Giving paclitaxel i.p. will lead to a “slow release” of the drug into 
the vascular compartment, with ensuing low peak plasma concentrations and reduced 
bioavailability compared to an i.v. injection [27]. In essence, the 12 mg paclitaxel/kg given i.p. 
represents a sub-therapeutic regime – as observed. The motivation for investigating such a 
design was to mimic a clinically relevant infusion regime with regards to plasma 
pharmacokinetics (PK) and to show one of the potential aspects of ACT; increasing therapeutic 
efficacy of a low dose/low toxicity regime. Abraxane®, on the other hand, was given i.v. at a 
low, but clinically relevant dose. In this case, plasma concentrations reach therapeutic levels 
and this design allowed for demonstrating ACTs potential for increasing therapeutic efficacy of 
a Standard of Care regime. Clearly, the difference between the two formulations also influences 
the PK of the active substance. The regular formulation releases paclitaxel from Chremophor 
micelles in the plasma after administration, where almost all of the drug (approx. 95%) is 
quickly being bound to human serum albumin (HSA) protein molecules in the blood stream 
[28]. In Abraxane®, the paclitaxel is pre-bound to HSA. Whereas it is contained in a nano-
particular structure upon injection, it immediately disintegrates to individual HSA-paclitaxel 
conjugates after administration [29]. It is the free paclitaxel that mediates the cytotoxic effect, 
but the HSA-paclitaxel complex is in equilibrium with its unit components and acts like a 
reservoir of free drug. In summary, the active moieties are identical between the two regimes 
investigated, but the PKs are significantly different. 
Our results clearly show the benefit of using ACT together with cytostatic drugs. Both in the 
“under dosed” paclitaxel group and with a clinically relevant dose of Abraxane®, we observe a 
very strong improvement in the anti-tumor activity of the drugs. This enhancement may be due 
to several possible mechanisms. 
The use of small, regular contrast microbubbles such as Sonovue® or Optison® in combination 
with US has been shown to induce a series of biomechanical effects that may influence the 
extravasation, distribution, uptake and efficacy of co-administered drugs [13-15]. A bubble in 
the vascular compartment, oscillating in the sound field, will exert direct forces on the 
endothelial cells creating deformations. Such deformations may influence the vascular 
permeability, and the morphology and fluid dynamics in the interstitium. In addition, strong 
shear force fields are created which increase the convection of fluid in the vascular 
compartment, and may lead to enhancement of various transcellular uptake mechanisms. 
Compared to using regular contrast microbubbles, all of the above noted mechanisms should 
be strongly enhanced by the ACT concept. The ACT bubble is approx. 1000 times bigger by 
volume [20, 21] and the level and range of the biomechanical effects induced should be orders 
of magnitude larger. In addition, the effects induced are strongly dependent upon the proximity 
of the bubble and the vessel wall [15]. Regular, free flowing microbubbles are typically moving 
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and at a distance, whereas the ACT bubbles are for a period in constant close contact with the 
endothelium over a significant segment [21]. Furthermore, regular microbubbles are typically 
cleared from the vasculature 2-3 minutes after injection, whereas ACT bubbles deposits and 
stay for 5-10 minutes [22]. Also, we postulate that ACT, in addition to regular microbubble 
mechanisms, could influence the pressure gradient between the vascular compartment and the 
interstitium. 
An oscillating ACT bubble will induce deformations of the vessel wall and the perivascular lining. 
This mechanical influence will pull the cells apart, generating or expanding fenestrations for 
enhanced permeability. Deformations of the endothelium can also result in disruptions in the 
interstitium and enhance the penetration of drug further into the tumor tissue. In essence, such 
mechanisms would represent an enhancement of the natural EPR effect. Targeting cancer cells 
using only EPR is not always a feasible strategy; the degree of tumor vascularization and 
porosity of tumor vessels can vary with the tumor type, status, and even throughout the same 
lesion [3, 30-34]. As the ACT concept mechanically modulates the vascular permeability and the 
interstitium, heterogeneity of the EPR effect, effectively hindering sufficient tumor delivery, 
may be circumvented.  
The oscillating ACT bubbles will also produce a significant shear stress and increased fluid 
convection (streaming patterns) in the vascular compartment. When endothelial cells are 
sensing shear stress they are stimulated to actively take up fluids and particles via endocytosis 
[35]. It is postulated that the transcellular transport of HSA-paclitaxel by endothelial cells via 
the GP-60 pathway [5, 6] might also be enhanced due to these effects, resulting in a higher 
paclitaxel concentration in the tumor tissue.  
Structures such as HSA bound paclitaxel are partly transported in the interstitium by 
convection; that is, they are carried by streaming of flowing fluid [36]. However, solid tumors 
show an increased interstitial fluid pressure (IFP), which forms a barrier to transcapillary 
transport [1, 37] and represents a significant obstacle in tumor treatment. Modification of the 
tumor interstitium might influence the IFP and facilitate the penetration of drugs into tumors 
[38-41]. In addition, when an ACT bubble deposits and occludes blood flow, the microvessel 
pressure will increase upstream of the bubble, influencing the transcapillary pressure gradient 
in favor of enhanced extravasation. 
Given i.p., the 12 mg paclitaxel/kg dose did not reach a therapeutic effect level. From similar 
studies reported in literature [42], this is not surprising – apparently the plasma concentration 
of paclitaxel does not reach levels to induce significant tumour regression. However, the tumor 
responses observed when combining this regimen with ACT clearly demonstrate a strong 
therapeutic effect. Although all tumours responded to PTX + ACT treatment, the therapeutic 
effect became distinctively biomodal  with time, with one group displaying full regrowth and 
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one group regressing into stable, complete remission. Such effects are not uncommon. The 
prostate tumor xenograft used in this study is reported to be poorly vascularized [43], and will 
contain regions of hypoxia. Cells in hypoxic regions have a decreased supply of nutrients and 
although they are viable they are slowly proliferating or quiescent. Paclitaxel is more effective 
against proliferating than quiescent cells and slowly proliferating cells at increasing distances 
from tumor blood vessels are likely to be more resistant to therapy [34]. Furthermore, the 
transport of hydrophobic compounds like paclitaxel is retarded by hydrophobic elastin layers. 
When stuck to a lipid pool, the paclitaxel will stay where it is, resulting in a high concentration 
of drug close to the vessel wall and low concentrations further into the tumor tissue. 
Consequently, the slowly proliferating cells that are more resistant to paclitaxel also experience 
the lowest exposure to the drug. This might be the reason why paclitaxel treatment in our study 
was insufficient for a significant fraction of animals. Although we postulate that ACT increase 
the extravasation and the interstitial fluid flow in the tumor tissue, at low plasma 
concentrations it may not always be sufficient to push this lipid pool-binding agent towards all 
tumor cells. As it has been hypothesized that a single remaining cancerous cell can grow into a 
new tumor, a successful therapy must eliminate all residual malignant tumor cells to be 
curative. In our case, even at the low dose investigated, we observe a curative response in 42% 
of the tumors. 
Given i.v., the 12 mg paclitaxel/kg dose with Abraxane® show, as expected, a strong therapeutic 
effect. Again, data clearly demonstrate a strong increase in therapeutic effect, when combined 
with ACT. As noted, the peak plasma concentration of paclitaxel is likely to be orders of 
magnitude higher with Abraxane® given i.v. vs. regular paclitaxel given i.p. [27]. With the 
Abraxane® regime, the enhancement in extravasation and/or improvement of uptake and 
distribution induced by the combinatory ACT treatment is sufficient to lead to an almost total 
eradication of cancerous cells. 
The reason for the complete depletion of the therapeutic effect of Abraxane® when combined 
with Sonazoid™ is not currently understood. However, in an effort to optimize biomechanical 
effects induced by Sonazoid™ microbubbles, the US Enhancement step for this group was 
performed by continuous insonation with 2.25 MHz and an MI of 0.4 for 5min and 45s. It is 
possible that this fairly strong and long regimen induce some kind of physiological response to 
shut down of the tumor vasculature, as has been reported elsewhere [24]. If so, this could 
prevent the drug penetrating tumor tissue and explain the lack of response in this group. 
Alternatively it could be due to some kind of physicochemical interaction e.g. Abraxane® 
adsorbing to the Sonazoid™ microbubbles after injection, being carried rapidly to the liver and 
lowering the plasma concentration to sub-therapeutic levels. Studies are under way to 
elucidate possible causes for this observation. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
14 
 
The ACT concept has been shown to strongly increase the therapeutic efficacy of both low and 
clinically relevant doses of chemotherapeutic drugs. In a clinical setting, ACT would represent 
an image guided, localized therapy; the activated bubbles produce copious US backscatter in 
regular B-mode imaging [21], giving the operator a tool for confirmation of the spatial 
distribution and level of bubble deposition. By its nature, ACT would be indicated towards 
diseases where it is clinically meaningful to treat known, solid tumors with medicinal therapy. A 
number of relevant clinical scenarios exists; most cases where chemotherapy is used as a neo-
adjuvant or adjuvant before/after surgical resection, and several diseases where a known, solid 
and non-resectable tumor is the primary reason for morbidity and mortality. A particularly 
interesting indication for ACT could be treatment of locally advanced, non-resectable 
pancreatic adenocarcinoma. These tumors are quite easily imaged by US [44], and the current 
standard of care for this condition (gemcitabine, optionally in combination with nab-paclitaxel) 
shows very limited clinical utility and could gain significantly from a combination regime with 
ACT. Alternatively, locally advanced, hormone-refractory prostate adenocarcinoma, often 
treated with taxanes, could represent an interesting clinical indication for ACT, as could triple 
negative breast cancer treated with doxorubicin or liver metastases from colon rectal cancer. 
Furthermore, ACT synergies are likely to be significant with a range of drugs; basically all that 
struggles with crossing the endothelial wall and penetrate the interstitium. As larger molecules/ 
structures such as cytokines, monoclonal antibodies, and nano-drugs are particularly hindered 
by this biological barrier, ACT may prove a versatile instrument for novel, emerging drug 
therapies as well as existing chemotherapies.  
Studies in orthotopic pancreatic adenocarcinoma models, including transgenic KRAS, treated 
with Abraxane® and/or gemcitabine are under way, as are triple negative negative breast 
cancer models treated with doxorubicin and Doxil™. Furthermore, mechanistic, 
pharmacokinetic and regulatory toxicity studies are planned for, and ACT is likely to enter into 
Phase I/IIa studies for treatment of non-resectable pancreatic cancer in 2018.  
5. Conclusions 
Proof of concept for Acoustic Cluster Therapy (ACT) has been demonstrated; ACT markedly 
increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human 
prostate adenocarcinoma in mice.  
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